Kimberly-Clark
KMB
$96.54
+0.66%
Kimberly-Clark is a leading global manufacturer of essential consumer goods, primarily operating in the household and personal products industry. Its core business revolves around personal care and consumer tissue products, with a brand portfolio that includes Huggies, Kleenex, Cottonelle, and Kotex. The company holds a dominant market position as a legacy incumbent in the tissue and hygiene realm, distinguished by its strong portfolio of everyday essential brands and a significant professional segment. The current investor narrative is heavily focused on its pending acquisition of Kenvue's consumer health portfolio slated for late 2026, a major strategic move aimed at diversification, while the stock contends with investor concerns over recent revenue declines and a significant price correction from its 52-week highs.…
KMB
Kimberly-Clark
$96.54
Related headlines
Investment Opinion: Should I buy KMB Today?
Rating: Hold. The core thesis is that KMB presents a high-risk, high-potential-reward situation where severe fundamental headwinds are balanced against a compelling valuation and a major strategic pivot, making it unsuitable for all but the most risk-tolerant, patient investors.
Supporting evidence includes a forward P/E of 12.66x, which prices in significant earnings recovery, and a dividend yield of 4.94% that is supported by robust $2.38B TTM free cash flow. However, these positives are counteracted by a 17.21% YoY revenue decline in Q4 2025 and a dangerously high debt-to-equity ratio of 4.77. Analyst sentiment is mixed and coverage is thin (only 3 analysts), indicating high uncertainty and lack of consensus direction.
The thesis would upgrade to Buy if revenue decline stabilizes to within -5% YoY for two consecutive quarters and the forward P/E remains below 14x. It would downgrade to Sell if revenue decline accelerates beyond -20% YoY, the dividend payout ratio exceeds 95% of free cash flow, or the stock breaks decisively below its 52-week low of $92.42. Relative to its own history, the stock is undervalued, but relative to its current financial risk profile, it is fairly valued, as the market is demanding a discount for the operational uncertainty and leverage.
Sign up to view all
KMB 12-Month Price Forecast
KMB is a battleground stock caught between a deep-value narrative and deteriorating fundamentals. The neutral stance reflects the high probability (50%) of a base case where the stock muddles through with minor declines, supported by its dividend but capped by its debt and growth challenges. The stance would upgrade to bullish on concrete evidence of revenue stabilization (e.g., two quarters of sequential growth) and a credible deleveraging plan post-Kenvue. It would downgrade to bearish on a breakdown below $92.42 or a dividend cut announcement. The next 12 months are a waiting game for the Kenvue deal and a turn in the operational cycle.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kimberly-Clark's 12-month outlook, with a consensus price target around $125.50 and implied upside of +30.0% versus the current price.
Average Target
$125.50
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$77 - $126
Analyst target range
Analyst coverage for Kimberly-Clark is limited, with only 3 analysts providing estimates, indicating this large-cap stock may have waning institutional interest or is perceived as having a stable, predictable outlook that requires less frequent analysis. The available data shows consensus estimates for EPS and revenue but does not provide a consensus price target or Buy/Hold/Sell distribution. This lack of a clear consensus target and the minimal number of analysts signal higher uncertainty and potentially less efficient price discovery. Recent institutional ratings from firms like Deutsche Bank (Hold), Piper Sandler (Overweight), and Citigroup (Sell) show a mixed but generally cautious sentiment, with no strong bullish consensus. The wide dispersion in analyst views—from Sell to Overweight—combined with the low coverage count, underscores the heightened debate around the stock's prospects as it navigates its current challenges and integrates a major acquisition.
Bulls vs Bears: KMB Investment Factors
The evidence currently tilts bearish, as the severe revenue decline and high financial leverage present immediate, quantifiable risks that outweigh the potential value opportunity. The bull case rests on a belief that the current valuation discount and strong cash flow have priced in the worst, and that the pending Kenvue acquisition will be a successful long-term catalyst. The single most important tension in the investment debate is whether the company's revenue trajectory can stabilize before its high debt load and margin pressures force a dividend cut or further operational deterioration. The resolution of this tension—specifically, the next few quarters of revenue growth—will determine if the stock is a deep-value turnaround or a value trap.
Bullish
- Deep Valuation Discount: The stock trades at a forward P/E of 12.66x, a significant discount to its trailing P/E of 16.63x, implying analyst expectations for an earnings rebound. This valuation is near the lower end of its historical range, having traded above 20x as recently as Q1 2025, suggesting a potential value opportunity if fundamentals stabilize.
- Robust Free Cash Flow & Dividend: The company generated $2.38 billion in TTM free cash flow, providing strong coverage for its substantial 4.94% dividend yield. The payout ratio of 82.14% is high but supported by this cash generation, offering income appeal amidst the price decline.
- Strategic Kenvue Acquisition Pending: The pending acquisition of Kenvue's consumer health portfolio in late 2026 is a major strategic pivot aimed at diversification. This could provide a long-term growth catalyst and re-rate the stock if successfully integrated, moving it beyond its core tissue and hygiene markets.
- Low Market Beta & Defensive Profile: With a beta of 0.31, the stock has historically exhibited low correlation to market swings, typical of a consumer staples company. Its 30% decline over the past year, while the S&P 500 gained 25%, represents significant idiosyncratic underperformance, which may be overdone given its defensive business model.
Bearish
- Severe Revenue Contraction: Q4 2025 revenue of $4.08B declined 17.21% YoY, continuing a multi-quarter downtrend from Q1's $4.84B. This top-line pressure is the primary driver of the stock's re-rating and raises questions about market share and pricing power for its essential brands.
- High Financial Leverage: A debt-to-equity ratio of 4.77 indicates a highly leveraged balance sheet, elevating financial risk. This is compounded by a current ratio of 0.75, suggesting potential liquidity constraints in covering short-term obligations.
- Profitability & Margin Pressure: The Q4 2025 operating margin of 12.43% shows compression from the TTM operating margin of 14.46%. While gross margins held at ~35.9%, the decline in operating income indicates rising costs or competitive pressures eroding profitability.
- Weak Technicals & Negative Momentum: The stock is down 30.17% over the past year and trades just 12% above its 52-week low of $92.42, reflecting persistent negative momentum. Its low beta of 0.31 makes this severe underperformance versus the market an outlier, signaling deep company-specific concerns.
KMB Technical Analysis
The stock is in a pronounced and sustained downtrend, having declined 30.17% over the past year. It is currently trading at $95.91, which is near the lower end of its 52-week range of $92.42 to $144.31, positioning it at approximately 12% above its 52-week low. This deep decline and proximity to multi-year lows suggest the stock is in a value-seeking zone, though it also reflects persistent negative momentum and fundamental challenges. Recent momentum remains weak, with the stock down 0.93% over the past month and down 12.34% over the past three months, indicating the bearish trend has continued unabated in the near term. This consistent negative performance, coupled with a very low beta of 0.31, suggests the stock has exhibited significant negative idiosyncratic risk, declining sharply even as the broader market (SPY) has posted strong gains of 25.19% over the past year. Key technical support is clearly defined at the 52-week low of $92.42, while major resistance sits at the 52-week high of $144.31. A sustained breakdown below $92.42 could signal a new leg down, whereas a recovery above the $100-$105 level would be a first step toward stabilization. The stock's low beta indicates it is typically far less volatile than the market, making its severe underperformance a notable outlier driven by company-specific factors.
Beta
0.31
0.31x market volatility
Max Drawdown
-35.3%
Largest decline past year
52-Week Range
$92-$144
Price range past year
Annual Return
-30.6%
Cumulative gain past year
| Period | KMB Return | S&P 500 |
|---|---|---|
| 1m | -2.3% | +4.0% |
| 3m | -10.2% | +8.2% |
| 6m | -5.7% | +11.5% |
| 1y | -30.6% | +24.3% |
| ytd | -4.8% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KMB Fundamental Analysis
Kimberly-Clark's revenue trajectory shows signs of pressure, with Q4 2025 revenue of $4.08 billion representing a year-over-year decline of 17.21%. This follows a sequential decline from Q3's $4.13 billion and Q2's $4.16 billion, indicating a multi-quarter trend of top-line contraction. The Consumer Tissue segment, a major business line, reported $1.52 billion in the latest period, but without segment growth rates, the overall decline suggests broad-based softness. The company remains profitable, posting net income of $499 million in Q4 2025, translating to a net margin of 12.23%. Gross margin for the quarter was 35.91%, which is consistent with the trailing twelve-month gross margin of 35.61%. However, operating income of $507 million in Q4 yields an operating margin of 12.43%, showing a slight compression from the 14.46% TTM operating margin, indicating some pressure on profitability. The balance sheet carries significant financial leverage, with a debt-to-equity ratio of 4.77, which is high and elevates financial risk. Positively, the company generated robust free cash flow of $2.38 billion over the trailing twelve months, providing ample coverage for its substantial dividend payout (payout ratio of 82.14%) and offering a measure of financial flexibility despite the elevated debt load. The current ratio of 0.75 indicates potential liquidity constraints in covering short-term obligations.
Quarterly Revenue
$4.1B
2025-12
Revenue YoY Growth
-0.17%
YoY Comparison
Gross Margin
+0.35%
Latest Quarter
Free Cash Flow
$2.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KMB Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. Kimberly-Clark trades at a trailing PE of 16.63x and a forward PE of 12.66x based on estimated EPS. The forward PE being meaningfully lower than the trailing multiple suggests analysts expect a significant recovery in earnings, likely factoring in cost-saving initiatives and the eventual contribution from the Kenvue acquisition. Compared to industry averages, the stock's valuation presents a mixed picture; its forward PE of 12.66x is not directly comparable without a sector benchmark, but its Price-to-Sales ratio of 1.95x and EV/Sales of 2.34x are typical for a mature consumer staples firm. Historically, the stock's own valuation has compressed dramatically from elevated levels; for instance, its trailing PE of 16.63x is near the lower end of its recent historical range, having traded above 20x as recently as Q1 2025. This contraction to a lower historical band reflects the market's downward re-rating in response to declining revenues and operational headwinds, presenting a potential value opportunity if the fundamentals stabilize.
PE
16.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 13x~114x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are elevated. The company's debt-to-equity ratio of 4.77 is exceptionally high, increasing vulnerability to rising interest rates and limiting financial flexibility. Concurrently, revenue has contracted 17.21% year-over-year in Q4 2025, creating a dangerous combination of declining top-line and high fixed financial obligations. The current ratio of 0.75 indicates potential short-term liquidity strain, and the 82.14% dividend payout ratio, while covered by free cash flow now, could become unsustainable if earnings decline further.
Market & Competitive Risks center on valuation compression and acquisition execution. The stock has already undergone a severe re-rating, with its trailing P/E compressing from over 20x to 16.63x. The primary external threat is the successful integration of the Kenvue acquisition slated for late 2026; failure to realize synergies or overpaying could exacerbate the balance sheet strain. Furthermore, the stock's low beta of 0.31 did not protect it from a 30% decline, demonstrating that company-specific risks have completely overridden its typical defensive characteristics, suggesting a breakdown in its historical investment profile.
The Worst-Case Scenario involves a continuation of revenue declines coupled with rising interest expenses, leading to an earnings miss that forces a dividend cut. This would shatter the income-investor thesis and trigger a further sell-off. The realistic downside is to the 52-week low of $92.42, representing a -3.6% decline from the current $95.91. A more severe bear case, factoring in a failed acquisition and credit rating downgrade, could see the stock test levels 20-25% below current prices, implying a loss in the mid-$70s range based on historical max drawdowns near -35%.
FAQ
The key risks are, in order of severity: 1) Financial Risk: Extremely high debt-to-equity ratio of 4.77 coupled with a weak current ratio of 0.75. 2) Operational Risk: Sustained revenue contraction, with Q4 2025 sales down 17.21% YoY. 3) Acquisition Risk: The pending Kenvue deal could strain the balance sheet further or fail to deliver expected synergies. 4) Dividend Risk: A high payout ratio of 82.14% could become unsustainable if earnings decline further, leading to a cut that would crater the stock.
The 12-month forecast presents three scenarios. The Base Case (50% probability) sees the stock trading between $100 and $110 as revenue decline moderates. The Bull Case (25% probability) targets $120-$130 on successful stabilization and acquisition optimism. The Bear Case (25% probability) warns of a drop to $80-$92 if revenue decline accelerates and the dividend is threatened. The Base Case is most likely, hinging on the assumption that free cash flow remains robust enough to maintain the current shareholder return policy despite top-line weakness.
KMB appears undervalued relative to its own history, with a trailing P/E of 16.63x near the lower end of its recent range. The forward P/E of 12.66x suggests the market expects an earnings recovery. However, this discount is justified by the company's operational challenges. Compared to a typical mature consumer staples firm, its Price-to-Sales of 1.95x and EV/Sales of 2.34x are in a fair range. The valuation implies the market expects continued fundamental pressure but is paying for the dividend and potential long-term strategic shift.
KMB is a speculative buy only for investors with a high risk tolerance and a long-term horizon. The 4.94% dividend yield and forward P/E of 12.66x are attractive, offering a potential margin of safety. However, the severe revenue decline (-17.21% YoY) and high debt load (D/E of 4.77) present substantial risks. It could be a good buy for a patient contrarian betting on a successful Kenvue acquisition and operational turnaround, but it is not suitable for conservative investors seeking stability or growth.
KMB is strictly a long-term investment with a suggested minimum holding period of 3-5 years. The stock's low beta of 0.31 suggests it is not a short-term trading vehicle, and its current thesis revolves around a multi-year turnaround and a major acquisition closing in late 2026. The high dividend yield is meant to compensate investors for this waiting period. Short-term traders would be better served by more volatile, catalyst-driven stocks, while long-term investors can potentially benefit from the valuation discount and strategic shift if they have the patience to endure further volatility.
